Cadrenal Therapeutics, Inc Common Stock

Cadrenal Therapeutics, Inc Common Stock

Yahoo Finance • 24 days ago

Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data

(RTTNews) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory setbacks. Positive data readouts spanned... Full story

Yahoo Finance • last month

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027; if warrants are exercised in... Full story

Yahoo Finance • 2 months ago

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki disease is the leading cause of acquired hea... Full story

Yahoo Finance • 2 months ago

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious... Full story

Yahoo Finance • 5 months ago

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are... Full story

Yahoo Finance • 8 months ago

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Cadrenal Therapeutics Inc. PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoag... Full story

Yahoo Finance • 9 months ago

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award

PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced its... Full story

Yahoo Finance • 9 months ago

Cadrenal Therapeutics GAAP EPS of -$1.31 beats by $0.18

* Cadrenal Therapeutics press release [https://seekingalpha.com/pr/20300656-cadrenal-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate] (CVKD [https://seekingalpha.com/symbol/CVKD]): Q3 GAAP EPS of -$1.31 b... Full story

Yahoo Finance • 9 months ago

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its f... Full story

Yahoo Finance • 10 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it... Full story

Yahoo Finance • 12 months ago

Cadrenal Therapeutics GAAP EPS of -$1.87

* Cadrenal Therapeutics press release [https://seekingalpha.com/pr/20195890-cadrenal-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:CVKD [https://seekingalpha.com/symbol/CVKD]): Q2 GAAP EPS of... Full story

Yahoo Finance • last year

Cadrenal Therapeutics director resigns; annual meeting set for September

Cadrenal Therapeutics , Inc. (NASDAQ:CVKD), a micro-cap biotech company with a market capitalization of $23.34 million, announced that Robert Lisicki has resigned from its board of directors, effective immediately, according to a statement... Full story